Showing results (901-910 of 932) with videos related to

Sort By:
Pageof 94
Cell Death & Disease|January 16, 2015
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)J D Leverson, H Zhang, J Chen, et al.
The American Journal of Clinical Nutrition|October 6, 2020
Knowledge gaps in understanding the metabolic and clinical effects of excess folates/folic acid: a summary, and perspectives, from an NIH workshopPadma Maruvada, Patrick J Stover, Joel B Mason, et al.
Cancers|December 11, 2022
Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian CancerLilian van Wagensveld, Juliette O A M van Baal, Maite Timmermans, et al.
Journal of Medicinal Chemistry|February 14, 2015
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivityMilan Bruncko, Le Wang, George S Sheppard, et al.
Molecular Cancer Therapeutics|June 16, 2005
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivoYan Luo, Alexander R Shoemaker, Xuesong Liu, et al.
BMC Medicine|January 8, 2024
Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 statusYuwei Wang, Gwen M H E Dackus, Efraim H Rosenberg, et al.
Molecular Cancer Therapeutics|April 15, 2026
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancerValentina Cutano, Shanade Dunn, Sungmi Park-Chouinard, et al.
Nature|January 24, 2020
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancerEmily J Faivre, Keith F McDaniel, Daniel H Albert, et al.
Molecular Cancer Therapeutics|May 5, 2017
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT InhibitorsJulie L Wilsbacher, Min Cheng, Dong Cheng, et al.
Science Translational Medicine|March 20, 2015
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D Leverson, Darren C Phillips, Michael J Mitten, et al.
Pageof 94